2020年

by 腫瘍病態学分野
  1. Ono T, Sasajima T, Shimizu H, Natsumeda M, Kanamori M, Asano K, Beppu T, Matsuda K, Ichikawa M, Fujii Y, Ohkuma H, Ogasawara K, Sonoda Y, Saito K, Nobusawa S, Nakazato Y, Kitanaka C, Kayama T, Tominaga T; Tohoku Brain Tumor Study Group. Molecular features and prognostic factors of pleomorphic xanthoastrocytoma: a collaborative investigation of the Tohoku Brain Tumor Study Group. Neurol Med Chir (Tokyo), 60(11):543-552, 2020.
  2. Tateishi K, Miyake Y, Kawazu M, Sasaki N, Nakamura T, Sasame J, Yoshii Y, Ueno T, Miyake A, Watanabe J, Matsushita Y, Shiba N, Udaka N, Ohki K,  Fink AL, Tummala S, Natsumeda M, Ikegaya N, Nishi M, Ohtake M, Miyazaki R, Suenaga J, Murata H, Aoki I, Miller JJ, Fujii Y, Ryo A, Yamanaka S, Mano H, Cahill DP, Wakimoto H, Chi AS, Batchelor TT, Nagane M, Ichimura K, Yamamoto T. A hyperactive RelA/p65-hexokinase 2 signaling axis drives primary central nervous system lymphoma. Cancer Res, 80(23):5330-5343, 2020. 
  3. Saito S, Hasegawa H, Sato D, Ando K, Motohashi K, Natsumeda M, Kikuchi B, Oishi M, Fujii Y. Endovascular revascularization for acute ischemic stroke related to blunt carotid injury: a case report. No Shinkei Geka, 48(6):527-532, 2020.(和)
  4. 棗田学，藤井幸彦，五十嵐博中．Current Topics: MRSの臨床応用に向けて 3脳腫瘍におけるMRSの利用．臨床画像，36(5):557-562, 2020. (和)
  5. Abe H, Natsumeda M, Okada M, Watanabe J, Tsukamoto Y, Kanemaru Y, Yoshimura J, Oishi M, Hashizume R, Kakita A, Fujii Y. MGMT expression contributes to temozolomide resistance in H3K27M-mutant diffuse midline gliomas. Front Oncol, 9:1568, 2020.